Leite Luiz R, Henz Benhur D, Macedo Paula G, Santos Simone N, Barreto José R, Zanatta André, Fenelon Guilherme, Cruz Filho Fernando E S
Grupo de Estudos em Arritmias Cardíacas/Fibrilação Atrial, Brasília DF, SMDB Conj., 16 Lote 5 Casa 1, Brasília 71680-160, DF, Brazil.
Future Cardiol. 2009 Mar;5(2):191-9. doi: 10.2217/14796678.5.2.191.
Catecholaminergic polymorphic ventricular tachycardia occurs in healthy children and young adults causing syncope and sudden cardiac death. This is a familial disease, which affect de novo mutation in 50% of the cases. At least two causative genes have been described to be localized in the chromosome 1; mutation of the ryanodine receptor gene and calsequestrin gene. The classical clinical presentation is syncope triggered by exercise and emotion in children and adolescents with no structural heart disease. Polymorphic ventricular tachycardia during treadmill testing, or after isoproterenol infusion, is the most common feature. Therapeutic options include, beta-blockers, calcium-channel blockers and, an implantable cardioverter defibrillator is indicated in high-risk patients. Risk stratification of this disease is very challenging, since some risk factors proved to be useful in some series but not in others. However, family history of sudden cardiac death and symptoms initiated in very young children are important predictors.
儿茶酚胺能多形性室性心动过速发生于健康儿童和年轻人,可导致晕厥和心源性猝死。这是一种家族性疾病,50%的病例存在新发突变。至少有两个致病基因已被描述定位于1号染色体;分别是兰尼碱受体基因和肌集钙蛋白基因的突变。典型的临床表现是无结构性心脏病的儿童和青少年在运动和情绪激动时引发的晕厥。在跑步机测试期间或异丙肾上腺素输注后出现多形性室性心动过速是最常见的特征。治疗选择包括β受体阻滞剂、钙通道阻滞剂,高危患者需植入心脏复律除颤器。这种疾病的风险分层极具挑战性,因为一些危险因素在某些系列研究中被证明有用,但在其他研究中并非如此。然而,心源性猝死家族史以及在幼儿期出现症状是重要的预测因素。